Search Results - "Vey, N."

Refine Results
  1. 1

    Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias by Itzykson, R, Kosmider, O, Cluzeau, T, Mansat-De Mas, V, Dreyfus, F, Beyne-Rauzy, O, Quesnel, B, Vey, N, Gelsi-Boyer, V, Raynaud, S, Preudhomme, C, Adès, L, Fenaux, P, Fontenay, M

    Published in Leukemia (01-07-2011)
    “…The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS…”
    Get full text
    Journal Article
  2. 2

    Construction and preliminary validation of a tool to measure the needs of adolescents and young adults (AYA) diagnosed with cancer: the QUestionnaire nEEd Cancer AYAs: QUEEC-AYAs by Justafré, S, Marino, P, Touzani, R, Dupeyre-Alvarez, F, Dantin, P, Viens, P, Vey, N, Calvin, S

    Published in Health and quality of life outcomes (23-04-2024)
    “…In France, 2300 adolescents and young adults (AYAs, 15-25 years old) are diagnosed with cancer each year. As soon as the disease is diagnosed, a number of…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6

    Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1 by Chaib, H, Nebbioso, A, Prebet, T, Castellano, R, Garbit, S, Restouin, A, Vey, N, Altucci, L, Collette, Y

    Published in Leukemia (01-04-2012)
    “…Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial by TAVERNIER, E, BOIRON, J.-M, TOURNILHAC, O, BUZYN, A, REMAN, O, CHARRIN, C, BOUCHEIX, C, GABERT, J, LHERITIER, V, VERNANT, J.-P, DOMBRET, H, THOMAS, X, HUJUET, F, BRADSTOCK, K, VEY, N, KOVACSOVICS, T, DELANNOY, A, FEGUEUX, N, FENAUX, P, STAMATOULLAS, A

    Published in Leukemia (01-09-2007)
    “…Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    A new Leukemia Prognostic Scoring System for refractory relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study by Chevallier, P, Labopin, M, Turlure, P, Prebet, T, Pigneux, A, Hunault, M, Filanovsky, K, Cornillet-Lefebvre, P, Luquet, I, Lode, L, Richebourg, S, Blanchet, O, Gachard, N, Vey, N, Ifrah, N, Milpied, N, Harousseau, J-L, Bene, M-C, Mohty, M, Delaunay, J

    Published in Leukemia (01-06-2011)
    “…A simplified prognostic score is presented based on the multivariate analysis of 138 refractory/relapsed acute myeloid leukaemia (AML) patients (median age 55…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome by Bouchacourt, B., Hospital, M. A., Zemmour, C., Rey, J., d’Incan, E., Charbonnier, A., Mohty, B., Saillard, C., Bonnet, S., Collignon, A., Gelsi-Boyer, V., Mozziconacci, M. J., Blaise, D., Vey, N.

    Published in Annals of hematology (01-04-2020)
    “…Although complete remission (CR) is achieved in 50 to 70% of older fit patients with acute myeloid leukemia (AML), consolidation therapy in this age group…”
    Get full text
    Journal Article
  20. 20

    Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study by Lacombe, F, Arnoulet, C, Maynadié, M, Lippert, E, Luquet, I, Pigneux, A, Vey, N, Casasnovas, O, Witz, F, Béné, M C

    Published in Leukemia (01-02-2009)
    “…An early appreciation of treatment efficacy could be very useful in acute myeloblastic leukemia (AML), and a prognostic value has been suggested for the…”
    Get full text
    Journal Article